Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

被引:1
|
作者
Zhang, Ran [1 ]
Lu, Xuan [2 ]
Tang, Liang V. [2 ]
Wang, Huafang [2 ]
Yan, Han [2 ]
You, Yong [2 ]
Zhong, Zhaodong [2 ]
Shi, Wei [2 ]
Xia, Linghui [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
haploidentical hematopoietic stem cell transplantation; graft composition; G-CSF-mobilized BM cells; G-CSF-mobilized PBSCs; total nucleated cells; MOBILIZED PERIPHERAL-BLOOD; PRIMED BONE-MARROW; POSTTRANSPLANT CYCLOPHOSPHAMIDE; CONDITIONING REGIMEN; LEUKEMIA; OUTCOMES; SURVIVAL;
D O I
10.3389/fimmu.2022.993419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05x10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20x10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Dendritic cell-based vaccines in patients with hematological malignancies
    Brugger, W
    Schneider, A
    Schammann, T
    Dill, P
    Grünebach, F
    Bühring, HJ
    Kanz, L
    Brossart, P
    HEMATOPOIETIC STEM CELLS 2000 BASIC AND CLINICAL SCIENCES, 2001, 938 : 359 - 363
  • [42] Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
    Nawas, Mariam T.
    Im, Annie
    Shaffer, Brian
    BLOOD ADVANCES, 2023, 7 (16) : 4475 - 4478
  • [43] Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key
    Fu, Haixia
    Xu, Lanping
    Liu, Daihong
    Zhang, Xiaohui
    Liu, Kaiyan
    Chen, Huan
    Wang, Yu
    Han, Wei
    Han, Tingting
    Huang, Xiaojun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (01) : 89 - 95
  • [44] Sexuality in patients undergoing haematopoietic stem cell transplantation
    Liptrott, Sarah Jayne
    Shash, Emad
    Martinelli, Giovanni
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (06) : 519 - 524
  • [45] Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML
    Impola, Ulla
    Larjo, Antti
    Salmenniemi, Urpu
    Putkonen, Mervi
    Itala-Remes, Maija
    Partanen, Jukka
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [46] Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-A meta-analysis and systematic review
    Li, Duihong
    Li, Xiaofan
    Liao, Lianming
    Li, Nainong
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2020, 10 (01): : 1 - 10
  • [47] Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: Analysis of clinical characteristics, nosocomial transmission and viral shedding
    Tabatabai, Julia
    Schnitzler, Paul
    Prifert, Christiane
    Schiller, Martin
    Weissbrich, Benedikt
    von Lilienfeld-Toal, Marie
    Teschner, Daniel
    Jordan, Karin
    Mueller-Tidow, Carsten
    Egerer, Gerlinde
    Giesen, Nicola
    PLOS ONE, 2022, 17 (07):
  • [48] Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
    Solves, Pilar
    Sanz, Jaime
    Gomez, Ines
    de la Puerta, Rosalia
    Arnao, Mario
    Montoro, Juan
    Luis Pinana, Jose
    Carretero, Carlos
    Balaguer, Aitana
    Guerreiro, Manuel
    Andreu, Rafa
    Rodriguez, Rebeca
    Montesinos, Pau
    Jarque, Isidro
    Ignacio Lorenzo, Jose
    Carpio, Nelly
    Angel Sanz, Miguel
    Francisco Sanz, Guillermo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 172 - 177
  • [50] Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients
    Almyroudis, Nikolaos G.
    Segal, Brahm H.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (12) : 1451 - 1466